A Year in Review
Monash IVF Group places great importance on partnering with doctors committed to delivering market-leading success rates and best-in-class patient experience.
In FY24, 20 new fertility specialists joined us through recruitment and business acquisition.
New Patient
Registrations increased by
494
↑ 6% on FY23
Employee Engagement
Culture of Success
67%
↑ 3% on FY23
Total domestic
stimulated cycles
11,401
↑ 10.4% on FY23
Australian Market Share
stimulated cycles
21.7%
↑ 1.5% on FY23
Average patient
NPS score
71.5
↑ +0.7% on FY23
Success rates4
increased by
1.5%
↑ 1.5% on FY23
Total Medical
Specialists
167
↑ 9.2% on FY23
New Day Surgeries
in Australia
2
↑ 100% on FY23
Revenue
$255m
↑ 19.4 on FY23
Underlying NPAT1,3
$29.9m
↑ 17.4% on FY23
Underlying EBITDA1,2
$62.8m
↑ 17.5% on FY23
Underlying EBIT1,2
$43.3m
↑ 13.7% on FY23
1. Non-IFRS measure
2. Refer to page 34 for reconciliation of Reported EBITDA, EBIT, and NPAT to Adjusted EBITDA, EBIT and NPAT
3. NPAT including minority interest
4. Clinical pregnancy rate per embryo transferred (woman aged < 43 years)
